F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: A contemporary clinical practice patterns study.
Adam Gondos,Luis Paz-Ares,Diego Saldana,Marlene Thomas,C. Mascaux,Lukas Bubendorf,Fabrice Barlesi +6 more
TL;DR: Current clinical patterns of guideline-mandated genomic testing in newly diagnosed US pts with aNSCLC are described and methods from the Flatiron Health electronic health record-de...
Journal ArticleDOI
LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
Edward B. Garon,Shao-Hua Lu,Yoshimitu Goto,Pedro De Marchi,Luiz Paz-Ares,David Spiegel,Matthew R. Thomas,J.C. Yang,Andrea Ardizzoni,Fabrice Barlesi,Sugandha Khanna,Claudia Bossen,Mariana Carbini,A. Yovine,Byoung Chul Cho +14 more
TL;DR: CAN was associated with significant reductions in NSCLC incidence and mortality, suggesting that CAN inhibition of the IL-1β pathway may have reduced the rate of progression, invasiveness, and metastatic spread of lung cancers undiagnosed at trial entry as mentioned in this paper .
Journal ArticleDOI
AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data.
Fabrice Barlesi,Arnaud Scherpereel,Radj Gervais,Vera Gorbunova,Anders Vikström,M-J. Ahn,Jonah Kim,Antonio Chella,Joachim G.J.V. Aerts,N. Ferrer,J. M. Trigo Perez,B. Lutiger,Achim Rittmeyer +12 more
TL;DR: 1L bev-cis-pem was well tolerated with a safety profile comparable to that of regimens indicated for use with bev; most AEs were G 1/2.
Journal ArticleDOI
P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC
Everett E. Vokes,Araba A. Adjei,M-J. Ahn,Fabrice Barlesi,Enriqueta Felip,Edward B. Garon,I. Grenga,A. Koenig,C. Martin,Tony Mok,Françoise Mornex,N. Munshi,David Raben,Cliff G. Robinson,Luis Paz-Ares +14 more
Journal ArticleDOI
CANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Luis Paz-Ares,Edward B. Garon,A. Ardizzoni,Fabrice Barlesi,Byoung Chul Cho,G. de Castro Junior,P. De Marchi,E. Felip,Yasushi Goto,Alastair Greystoke,Shun Lu,D.W-T. Lim,Vassiliki A. Papadimitrakopoulou,Martin Reck,Ben Solomon,David R. Spigel,D.S.W. Tan,Michael Thomas,J.C-H. Yang,Bruce E. Johnson +19 more